Ingelheim, Germany | January 29, 2026 — Boehringer Ingelheim announced positive results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor, in people living with primary focal segmental glomerulosclerosis (FSGS). The investigational therapy achieved a 40% reduction in proteinuria in the 20 mg dose group compared to placebo, a clinically meaningful outcome in a rare, progressive kidney disease with no approved disease-modifying treatments.
Science Significance
From a scientific perspective, the results validate TRPC6 inhibition as a promising, targeted approach in FSGS. In primary FSGS, overactivation of the TRPC6 channel on podocytes leads to excessive calcium influx, podocyte injury, and progressive loss of the kidney’s filtration function, resulting in proteinuria and disease progression. Apecotrep directly targets this disease-driving mechanism, aiming to protect podocytes and slow renal decline rather than suppressing the immune system. In the Phase II trial, 35% of patients receiving apecotrep achieved a ≥25% reduction in urine protein-creatinine ratio (UPCR) across dose groups, with the strongest response seen in the 20 mg cohort, reinforcing the biological relevance of the target and dose-dependent efficacy.
Regulatory Significance
The findings have notable regulatory implications as apecotrep advances into late-stage development. The asset has already received Breakthrough Therapy Designation from China’s Center for Drug Evaluation (CDE) and Orphan Drug Designations from the European Medicines Agency (EMA) and Japan’s Ministry of Health, Labour and Welfare (MHLW). These designations reflect both the high unmet medical need in primary FSGS and the strength of early clinical data. A global Phase III trial (NCT07220083) is now recruiting adults and adolescents, while an additional Phase II study (NCT07355296) is planned to explore efficacy in other proteinuric kidney diseases, supporting a broader regulatory strategy under GCP-compliant development pathways.
Business Significance
Advertisement
Strategically, apecotrep strengthens Boehringer Ingelheim’s Cardiovascular–Renal–Metabolic portfolio and reinforces its long-term commitment to kidney disease innovation. As a potential first-in-class, oral therapy, apecotrep represents a differentiated asset in a field historically dominated by off-label immunosuppressive treatments. Successful progression into Phase III enhances the program’s value creation potential, positioning Boehringer Ingelheim as a leader in rare renal diseases. The publication of data in a high-impact, peer-reviewed journal and presentation at a major nephrology congress further support scientific credibility and stakeholder confidence.
Patients’ Significance
For patients, the results are particularly meaningful. Primary FSGS is a rare but severe disease, with approximately 50% of patients progressing to end-stage kidney disease within 5–10 years. Current treatment options are limited, often poorly tolerated, and do not directly address the underlying cause of the disease. A therapy like apecotrep, which is oral, once daily, and non-immunosuppressive, could significantly reduce treatment burden while offering the possibility of slowing disease progression. A sustained reduction in proteinuria is strongly associated with better long-term renal outcomes, making these findings highly relevant to patient quality of life and survival.
Policy Significance
At the policy level, the advancement of apecotrep aligns with global priorities to accelerate innovation in rare diseases through regulatory incentives such as orphan and breakthrough designations. These frameworks encourage pharmaceutical investment in conditions with limited commercial markets but substantial public health impact. The program also highlights the importance of biomarker-driven clinical endpoints, such as proteinuria reduction, in enabling more efficient and evidence-based regulatory decision-making for rare kidney diseases.
Overall, the Phase II results for apecotrep in primary FSGS represent a significant milestone in kidney disease drug development. By demonstrating clinically meaningful proteinuria reduction, favorable tolerability, and a clear mechanistic rationale, the investigational therapy advances the prospect of a first disease-modifying treatment for this devastating condition. For the cGxP.wire audience, the announcement underscores the convergence of rigorous clinical science, regulatory acceleration, and patient-centered innovation shaping the future of rare renal therapeutics.
Source: Boehringer Ingelheim press release
